HSA
RCEL icon

Hussman Strategic Advisors’s Avita Medical RCEL Stock Holding History

Hussman Strategic Advisors’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-42,000
Closed -$333K – 279
2024
Q2 		$333K Hold
42,000
– – 0.09% 199
2024
Q1 		$673K Buy
+42,000
New +$680K 0.16% 168

Other funds holding RCEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hussman Strategic Advisors's RCEL Position: Q3 2024 in Review

Hussman Strategic Advisors sold out of Avita Medical (RCEL) in Q3 2024, closing a stake of 42,000 shares — an estimated $333K sold.

Hussman Strategic Advisors first reported a position in RCEL in Q1 2024 and held it in 2 quarters. The position peaked at $673K in Q1 2024. 67 funds tracked by Wall St. Rank hold RCEL as of Q3 2024.

  • Hussman Strategic Advisors reported no remaining Avita Medical position as of Q3 2024 after selling out during the quarter.
  • Hussman Strategic Advisors sold 42,000 Avita Medical shares in Q3 2024, an estimated $333K.
  • Hussman Strategic Advisors first reported a position in Avita Medical in Q1 2024 and held it in 2 quarters.
  • Hussman Strategic Advisors's Avita Medical position peaked at $673K in Q1 2024.
  • 67 funds tracked by Wall St. Rank held Avita Medical as of Q3 2024.

Based on Hussman Strategic Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.